3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
5
Lung Neoplasms
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Hematologic Neoplasms
2
Solid Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Lymphoma
1
Lung Diseases
1
Genomic Instability
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Neoplasms
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
ALK+ Advanced NSCLC
1
Interventions
Gemcitabine
33
Cisplatin
28
pembrolizumab
19
durvalumab
17
Oxaliplatin
16
Fluorouracil
16
Leucovorin
14
Magnetic Resonance Spectroscopy
13
Specimen Handling
9
Biopsy
9
lenvatinib
7
Nivolumab
7
Capecitabine
7
Taxes
6
Paclitaxel
6
Irinotecan
6
fludarabine
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
pemigatinib
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
Floxuridine
4
Cyclophosphamide
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
tremelimumab
3
olaparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
alectinib
×
1 year
×
Clear all
No trials found.